Blau Farmacêutica is a leading Brazilian multinational corporation in the institutional pharmaceutical segment, focused on the institutional and hospital markets, as well as a biotechnology pioneer in the country.
We are a publicly-held company listed on the Brazilian Stock Exchange (B3) under the ticker “BLAU3”. Our commitment is to offer innovative, highly complex drugs, ensuring effectiveness, safety and quality to provide patients with the best therapy option, as defined by the medical team and/or healthcare professionals.
With our own portfolio of highly complex drugs, we cover areas such as immunology, hematology, oncology, nephrology, infectology, anesthesiology, among others.
We are present in Latin America, including Argentina, Chile, Colombia, Ecuador, Peru and Uruguay, in the United States through Hemarus (our plasma collection centers), and in Europe with an equity interest in Prothya, a plasma fractionator with its own drugs marketed globally.
We operate five pharmaceutical plants in Brazil and an API (Active Pharmaceutical Ingredient) plant, equipped with cutting-edge technology and integrated monitoring and control systems, following the most stringent good practice standards of international regulatory agencies.